Findings

What do systematic reviews say?

14 questions · 14 findings · 6 reviews · Gut

Sort:Best matchNewest Highest certainty Download CSV

No studies found 6 · 42.9%GRADE not reported 0 · 0%Very low 4 · 28.6%Low 2 · 14.3%Moderate 2 · 14.3%High 0 · 0%

Biological therapy vs placebo, best supportive care (BSC) or no treatment

QoL · advanced gastric and oesophago‐gastric junction adenocarcinoma

1 finding from 1 review

Salvage systemic therapy for advanced gastric and oesophago‐gastric junction adenocarcinoma 2020 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 283 participants
Low

Chemmotherapy combined with biological therapy vs chemotherapy alone

QoL · advanced gastric and oesophago‐gastric junction adenocarcinoma

Chemmotherapy combined with biological therapy showed no clear difference in quality of life (QoL) compared with chemotherapy (low certainty).

1 finding from 1 review

Salvage systemic therapy for advanced gastric and oesophago‐gastric junction adenocarcinoma 2020 · Cochrane Headline outcomes only
HR 0.88 [0.74, 1.04]
2 studies · 1154 participants
Low

Biofeedback vs hypnotherapy

QoL · people with irritable bowel syndrome

The review found no eligible studies for this question.

1 finding from 1 review

Biofeedback for treatment of irritable bowel syndrome 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Biofeedback plus standard therapy vs usual care

QoL · people with irritable bowel syndrome

The review found no eligible studies for this question.

1 finding from 1 review

Biofeedback for treatment of irritable bowel syndrome 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Biofeedback vs counseling

QoL · people with irritable bowel syndrome

1 finding from 1 review

Biofeedback for treatment of irritable bowel syndrome 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 29 participants
Very low

Multi‐component psychological intervention (with biofeedback) vs no intervention

QoL · people with irritable bowel syndrome

The review found no eligible studies for this question.

1 finding from 1 review

Biofeedback for treatment of irritable bowel syndrome 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Multi‐component psychological intervention (with biofeedback) vs attention control

QoL · people with irritable bowel syndrome

The review found no eligible studies for this question.

1 finding from 1 review

Biofeedback for treatment of irritable bowel syndrome 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Biofeedback vs relaxation training

QoL · people with irritable bowel syndrome

The review found no eligible studies for this question.

1 finding from 1 review

Biofeedback for treatment of irritable bowel syndrome 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Biofeedback plus standard therapy vs sham biofeedback plus standard therapy

QoL · people with irritable bowel syndrome

The review found no eligible studies for this question.

1 finding from 1 review

Biofeedback for treatment of irritable bowel syndrome 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings: Molecular‐targeted therapy plus chemotherapy vs chemotherapy alone

Health status and quality of life · people with advanced gastric cancer

1 finding from 1 review

Molecular‐targeted first‐line therapy for advanced gastric cancer 2016 · Cochrane Headline outcomes only
no estimate extracted
1 study · 53 participants
Very low

Acupuncture vs sham

QoL · people with irritable bowel syndrome

1 finding from 1 review

Acupuncture for treatment of irritable bowel syndrome 2012 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 253 participants
Moderate

Intervention not reported

Quality of life (QoL) Inflammatory Bowel Disease Questionnaire (IBDQ) (scale: 32 to 224; higher score = better QoL) · Patients with active Crohn's disease

1 finding from 1 review

Adalimumab for induction of remission in Crohn's disease 2019 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 714 participants
Moderate

Intervention not reported

Self‐perceived QoL (change from baseline) measured using Peds QL 4.0 Generic Core Scales, scoring 0‐100 points, higher score indicates better quality of life) · children with chronic constipation

1 finding from 1 review

Transcutaneous electrical stimulation (TES) for treatment of constipation in children 2016 · Cochrane Headline outcomes only
no estimate extracted
1 study · 33 participants
Very low

Intervention not reported

Parent‐perceived QoL (change from baseline) measured using PedsQL 4.0 Generic Core Scales, scoring 0‐100 points, higher score indicates better quality of life) · children with chronic constipation

1 finding from 1 review

Transcutaneous electrical stimulation (TES) for treatment of constipation in children 2016 · Cochrane Headline outcomes only
no estimate extracted
1 study · 33 participants
Very low